BridgeBio Pharma Operating Expenses 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly operating expenses history and growth rate from 2018 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
- BridgeBio Pharma operating expenses for the quarter ending June 30, 2024 were $0.178B, a 20.28% increase year-over-year.
- BridgeBio Pharma operating expenses for the twelve months ending June 30, 2024 were $0.729B, a 36.01% increase year-over-year.
- BridgeBio Pharma annual operating expenses for 2023 were $0.617B, a 4.55% increase from 2022.
- BridgeBio Pharma annual operating expenses for 2022 were $0.59B, a 8.74% decline from 2021.
- BridgeBio Pharma annual operating expenses for 2021 were $0.646B, a 33.89% increase from 2020.
BridgeBio Pharma Annual Operating Expenses
(Millions of US $) |
| 2023 |
$617 |
| 2022 |
$590 |
| 2021 |
$646 |
| 2020 |
$483 |
| 2019 |
$307 |
| 2018 |
$184 |
| 2017 |
$44 |
BridgeBio Pharma Quarterly Operating Expenses
(Millions of US $) |
| 2024-06-30 |
$178 |
| 2024-03-31 |
$211 |
| 2023-12-31 |
$179 |
| 2023-09-30 |
$162 |
| 2023-06-30 |
$148 |
| 2023-03-31 |
$128 |
| 2022-12-31 |
$131 |
| 2022-09-30 |
$129 |
| 2022-06-30 |
$154 |
| 2022-03-31 |
$175 |
| 2021-12-31 |
$179 |
| 2021-09-30 |
$152 |
| 2021-06-30 |
$148 |
| 2021-03-31 |
$168 |
| 2020-12-31 |
$128 |
| 2020-09-30 |
$128 |
| 2020-06-30 |
$125 |
| 2020-03-31 |
$102 |
| 2019-12-31 |
$92 |
| 2019-09-30 |
$81 |
| 2019-06-30 |
$69 |
| 2019-03-31 |
$64 |
| 2018-12-31 |
|
| 2018-09-30 |
$41 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.045B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
